Top Industry Leaders in the Asthma Devices Market
Latest Asthma Devices Companies Updates:
Flovent Discontinuation: GSK's discontinuation of Flovent HFA, a popular corticosteroid inhaler, at the start of 2024, has caused concerns for patients facing insurance hurdles and potential cost issues with the authorized generic version.
Symbicort Transition: AstraZeneca announced the planned discontinuation of Symbicort in certain markets by 2025, focusing on newer inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combinations like Breztri Aerosphere.
Teva's ProAir Respiclar 160HFA Approval: The FDA approved Teva's generic version of ProAir Respiclar 160 HFA, an albuterol rescue inhaler, offering a potential cost-effective option for patients.
Trudell Medical's Trudell Medical Microhaler Launch: Trudell Medical launched its Microhaler, a new dry powder inhaler designed for easier portability and use, particularly for children and elderly patients.
List of Asthma Devices Key companies in the market:
- GlaxoSmithKline plc. (Europe)
- Merck & Co., Inc. (U.S.)
- 3M (U.S.)
- Aristopharma Ltd. (Asia Pacific)
- SRS PHARMACEUTICALS PVT. LTD. (Asia Pacific)
- AstraZeneca (Europe), Baxter. (U.S.)
- Boehringer Ingelheim GmbH (Europe)
- Koninklijke Philips N.V. (Europe)